Search form



CL Mobile Menu

ADA 2014

ADA 2014

(ACR2014) Mood disorders are common among lupus patients, but the lupus symptoms appear not to be the direct cause in many cases, according to an international study.

How does "pattern care" differ from "step therapy"? Does the bionic pancreas work? Why is incretin therapy taking off? Here, a 5-slide review of these and other hot topics from the 2014 ADA Scientific Sessions.

Posters at ADA 2014 showcased growing popularity of the incretin therapies and SGLT2 inhibitors. Most fascinating to this diabetologist blogger was use of insulin and a GLP-1 RA in a fixed-combination product.

Improvement in overall diet quality lowers the risk of type 2 diabetes, a new study shows. This is independent of other healthful behaviors, including increased physical activity and body weight loss.

New guidelines for the treatment of patients with high cholesterol may, or may not, be appropriate for persons with type 2 diabetes. Here are the pros and cons.

Activation of opioid receptors with novel approaches may prevent hypoglycemia and lead to safer intensive glycemic control, according to a study reported at the American Diabetes Association 74th Scientific Sessions.

The latest version of this wearable, automated device can improve glycemia without increasing hypoglycemia. It can handle a wide range of dosing requirements.


Subscribe to ADA 2014 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.